Pharmamarketeer

Daiichi Sankyo phase 3 ELDERCARE AF study of anticoagulant, edoxaban in non ─ valvular atrial fibrillation & high bleeding risk meets primary endpoint

Phase 3

Daiichi Sankyo Company Limited announced that the primary endpoint has been achieved in the Japan phase 3 clinical trial (ELDERCARE AF Study) for the anticoagulant, edoxaban, in elderly patients with non─valvular atrial fibrillation and high bleeding risk.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl